Lepidoglyphus destructor allergens (Lep d)

Lepidoglyphus destructor allergens are a group of potent allergenic proteins produced by the storage mite L. destructor, which is prevalent in both agricultural settings (e.g., hay and grain storage) and urban domestic environments [1, 3, 9]. The major allergen, Lep d 2, belongs to the NPC2 family and features an MD-2-related lipid recognition (ML) domain, while other characterized allergens include tropomyosins and fatty acid-binding proteins [6, 13, 16]. Sensitization to these proteins occurs primarily through inhalation and is a significant cause of IgE-mediated respiratory diseases, including allergic rhinitis and asthma, as well as skin conditions like atopic dermatitis [3, 7, 14]. In a therapeutic context, these allergens are used as the active components in diagnostic tools and allergen-specific immunotherapy (AIT) products [4, 8, 12]. Immunotherapy works by gradually exposing the patient's immune system to increasing doses of the allergen to induce desensitization and long-term tolerance, effectively reducing symptoms and the need for symptomatic medication [1, 11, 15]. Therapeutic challenges include the risk of inducing systemic allergic reactions, necessitating careful dose titration and clinical monitoring during administration [1, 12].

Other names

Storage mite allergensGroceries mite allergensSugar mite allergensLep d proteinsLepidoglyphus destructor extract

Allergen-specific immunotherapy (AIT) utilizing these proteins aims to induce long-term immunological tolerance by shifting the immune response from a Th2-mediated allergic profile to a Th1/Treg-mediated tolerant profile, often characterized by the production of allergen-specific IgG4 antibodies which act as blocking antibodies [1, 12, 15].